Brokers Issue Forecasts for ALX Oncology Holdings Inc.’s FY2023 Earnings (NASDAQ:ALXO)

ALX Oncology Holdings Inc. (NASDAQ:ALXOGet Rating) – Investment analysts at Cantor Fitzgerald issued their FY2023 earnings per share estimates for shares of ALX Oncology in a research note issued on Monday, June 6th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings per share of ($3.01) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock.

A number of other research analysts also recently issued reports on ALXO. Stifel Nicolaus reduced their price target on shares of ALX Oncology from $35.00 to $16.00 in a research report on Monday. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of ALX Oncology in a research note on Monday, May 16th. Piper Sandler lowered their price objective on shares of ALX Oncology from $70.00 to $48.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 18th. Finally, Zacks Investment Research raised shares of ALX Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, May 10th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $52.14.

Shares of ALXO stock opened at $7.75 on Wednesday. The firm has a market cap of $315.27 million, a P/E ratio of -3.35 and a beta of 2.73. ALX Oncology has a 1-year low of $7.01 and a 1-year high of $81.19. The firm has a fifty day moving average of $12.35 and a two-hundred day moving average of $17.71.

ALX Oncology (NASDAQ:ALXOGet Rating) last released its quarterly earnings data on Monday, May 9th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.17.

A number of hedge funds and other institutional investors have recently bought and sold shares of ALXO. Nisa Investment Advisors LLC bought a new position in shares of ALX Oncology during the 4th quarter worth approximately $48,000. ACT Capital L.L.C. acquired a new stake in ALX Oncology during the 3rd quarter valued at $111,000. Quantbot Technologies LP lifted its holdings in ALX Oncology by 338.3% during the 1st quarter. Quantbot Technologies LP now owns 7,100 shares of the company’s stock valued at $119,000 after purchasing an additional 5,480 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in ALX Oncology during the 4th quarter worth $121,000. Finally, EDBI Pte Ltd bought a new position in ALX Oncology during the 4th quarter worth $121,000. 89.42% of the stock is owned by institutional investors and hedge funds.

About ALX Oncology (Get Rating)

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors.

See Also

Earnings History and Estimates for ALX Oncology (NASDAQ:ALXO)

Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with's FREE daily email newsletter.